DOI: https://doi.org/10.22141/2224-0713.5.91.2017.110859

Antiepileptic, neuroprotective and antihyperalgesic effects of levetiracetam

I.V. Romanenko, V.I. Romanenko, Yu.I. Romanenko

Abstract


The article presents a review of the literature on the mechanisms of action of levetiracetam, results of studies on the effectiveness of the drug as an antiepileptic, neuroprotective and antihyperalgesic agent.

Keywords


levetiracetam; epilepsy; anticonvulsant; neuroprotection; hyperalgesia

References


Bahr O., Hermisson M., Rona S., Rieger J., Nussbaum S., Kortvelyessy P. et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO Trial // Acta Neurochir. (Wien). — 2012. — 154. — 229-35.

Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monothe­rapy // Epilepsia. — 2000. — 41 (10). — 1276-83.

Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U. Placebo-controlled study of levetiracetam in idiopathic genera­lized epilepsy // Neurology. — 2007. — 30 (69). — 1751-60.

Brighina F., Palermo A., Aloisio A., Francolini M., Giglia G., Fierro B. Levetiracetam in the prophylaxis of migraine with aura: A 6-month open-label study // Clin. Neuropharmacol. — 2006. — 29. — 338-42.

Brodie M.J., Perucca E., Ryvilin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled release carbamazepine in newly diagnosed epilepsy // Neurology. — 2007. — 68. — 402-8.

Chin-Wei Huang, Ming-Chyi Pai, Jing-Jane Tsai. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy // Psychiatry and Clinical Neurosciences. — 2008. — 62. — 548-553.

Christoph Helmstaedter, Juri-Alexander Witt. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: A non-interventional surveillance trial //Epilepsy and Behavior. — 2010. — 18. — 74-80.

Cormier J., Catherine J.C. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age // Neuropsychiatr. Dis. Treat. — 2013. — 9. — 295-306.

Falah M., Madsen C., Holbech J.V., Sindrup S.H. A rando­mized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis // Eur. J. Pain. — 2012. — 16. — 860-9.

Gurses C., Alpay K., Ciftci F.D., Bebek N., Baykan B., Gokyigit A. The efficacy and tolerability of levetiracetam as an add-on therapy in patients with startle epilepsy // Seizure. — 2008. — 17. — 625-30.

Jones K.E., Puccio A.M., Harshman K.J., Falcione B., Benedict N., Jankowitz B.T. et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury // Neurosurg.

Focus. — 2008. — 25. — 1-10.

Kozlowski P., Czepińska-Ćwik W., Kozlowska M., Kozlowska K. Levetiracetam-epilepsy treatment, pharmacokinetics, mechanism of action, interaction and toxicity // J. Educ. Health Sport. — 2015. — 5. — 143-50.

Lambrechts D.A.J.E., Sadzot B., van Paesschen W., van Leusdend A., Carpaye J., Bourgeois P. et al. Efficacy and safety of levetiracetam in clinical practice: Results of the SKATETM trial from Belgium and The Netherlands // Seizure. — 2006. — 15. — 434-42.

Lee Y.J., Kang H.C., Kim H.D., Lee J.S. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy // Pediatr. Neurol. — 2010. — 42. — 86-92.

Lim D.A., Chang E., Burt M., Chang S., Lamborn K.R., Tarapore L. et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study // J. Neurooncol. — 2009. — 93. — 349-54.

Loscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations // Epilepsy Res. — 1988. — 2. — 145-81.

Mariana Lopez-Gongora, Alejandro Martlnez-Dameno, Carmen Garcia, Antonio Escartfn Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study // Epileptic. Disord. — 2008. — 10 (4). — 297-305.

Marini H., Costa C., Passaniti M., Esposito M., Campo G.M., Ientile R. et al. Levetiracetam protects against kainic acid-induced to­xicity // Life Sci. — 2004. — 74. — 1253-64.

Mendoza-Torreblanca J.G., Vanoye-Carlo A., Phillips-Farfa V.B., Carmona-Aparicio L., Gómez-Lira G. Synaptic vesicle protein 2A: Basic facts and role in synaptic function // Eur. J. Neurosci. — 2013. — 38. — 3529-39.

Micov A., Tomic M., Popovic B., Stepanovic-Petrovic R. The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: Mechanism of action // Br. J. Pharmacol. — 2010. — 161. — 384-92.

Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., Magnus L. The KEEPER trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study // Epilepsy Res. — 2003. — 54. — 153-61.

Oliveira A.A., Almeida J.P., Freitas R.M., Nascimento V.S., Aguiar L.M., Júnior H.V. et al. Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures // Cell. Mol. Neurobiol. — 2007. — 27. — 395-406.

Ozcan M., Ayar A., Canpolat S., Kutlu S. Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy // Acta Anaesthesiol. Scand. — 2008. — 52. — 926-30.

Rossi S., Mataluni G., Codecà C., Fiore S., Buttari F., Musel­la A. et al. Effects of levetiracetam on chronic pain in multiple sclerosis: Results of a pilot, randomized, placebo-controlled study // Eur. J. Neurol. — 2009. — 16. — 360-6.

Steinbaugh L.A., Lindsell C.J., Shutter L.A., Szaflarski J.P. Initial EEG predicts out- comes in a trial of levetiracetam vs. fosphenytoin for seizure prevention // Epilepsy Behav. — 2012. — 23. — 280-4.

Stepanovic-Petrovic R.M., Micov A., Tomic M., Ugresic N.D. The local peripheral antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain model // Anesth. Analg. — 2012. — 115. — 1457-66.

Swaroop H.S., Ananya C., Nithin K., Jayashankar C.A., Satish Babu H.V., Srinivas B.N. Levetiracetam: A review of its use in the treatment of epilepsy // Int. J. Med. Biomed. Res. — 2013. — 2. — 166-72.

Szaflarski J.P., Sangha K.S., Lindsell C.J., Shutter L.A. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis // Neurocrit. Care. — 2010. — 12. — 165-72.

Tony Wua, Chih-Chuan Chen, Ta-Cheng Chen, Yuan-Fu Tseng, Chen-Bang Chiang, Chin-Chuan Hung, Horng-Huei Liou. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: An open-label multicenter study // Epilepsy & Behavior. — 2009. —16. — 468-474.

Wang H., Gao J., Lassiter T.F., McDonagh D.L., Sheng H., Warner D.S. et al. Levetiracetam is neuroprotective in murine mo­dels of closed head injury and subarachnoid hemorrhage // Neurocrit. Care. — 2006. — 5. — 71-8.

Weinstock A., Ruiz M., Gerard D., Toublanc N., Stockis A., Faroo O. et al. Prospective open-label, single-arm, multicenter, safety, tolerability and pharmacokinetic studies of intravenous levetiracetam in children with epilepsy // J. Child Neurol. — 2013. — 28. — 1423-9.

Zachenhofer I., Donat M., Oberndorfer S., Roessler K. Peri­operative levetiracetam for prevention of seizures in supratentorial brain tumor surgery // J. Neuro Oncol. — 2011. — 101. — 101-6.




Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта